| Literature DB >> 31831536 |
Zhuanlan Sun1, Demi Zhu2.
Abstract
OBJECTIVES: Outdoor air pollution is a serious environmental problem worldwide. Current systematic reviews (SRs) and meta-analyses (MAs) mostly focused on some specific health outcomes or some specific air pollution.Entities:
Keywords: evidence gap map; health outcomes; outdoor air pollution
Year: 2019 PMID: 31831536 PMCID: PMC6924861 DOI: 10.1136/bmjopen-2019-031312
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Inclusion and exclusion criteria used in this EGM for eligible studies
| Inclusion criteria | Exclusion criteria |
| Study types | Study type |
| SRs and MAs | Indoor air pollution |
| Study methods | Primary studies |
| Quantitative SRs | Study methods |
| Study conclusion | Qualitative reviews only |
| Data supported outcomes relevant to outdoor air pollution |
EGM, evidence gap map; MAs, meta-analyses; SRs, systematic reviews.
Information to be collected during the data extraction stage
| Study design | Study population | Exposures | Outcome information |
| Author(s) | Sample size | Types of air pollution | Health outcomes |
| Publication Year | Study region | Key results | |
| Location of the corresponding author(s) | Target population | ||
| Publication journal disciplinea | |||
| Study design | |||
| Study duration | |||
a: The discipline catalogue is from the Journal Citation Report published by Web of Science.
Figure 1Systematic literature search process for eligible SRs and MAs. SR, systematic review; MA, meta-analysis.
General descriptions of the included SRs and MAs
| (n=86) | N | % | N | % | |
| Continent* | Number of original studies | ||||
| Africa | 1 | 1 | <10 studies | 10 | 12 |
| Australia | 2 | 2 | 10~30 studies | 46 | 53 |
| South America | 3 | 3 | 30~60 studies | 13 | 15 |
| North America | 19 | 22 | >60 studies | 13 | 15 |
| Asia | 29 | 34 | Not clearly mentioned | 4 | 5 |
| Europe | 32 | 37 | Study period | ||
| Countries of primary studies included in the SRs and MAs | <10 years | 11 | 13 | ||
| <5 countries | 18 | 21 | 10~20 years | 23 | 27 |
| 5~10 countries | 27 | 31 | >20 years | 7 | 8 |
| 10~20 countries | 15 | 17 | Not clearly mentioned | 45 | 52 |
| >20 countries | 1 | 1 | Types of study designs | ||
| Not clearly mentioned† | 25 | 29 | Single | 13 | 15 |
| Population | Multiple | 73 | 85 | ||
| Infants | 2 | 2 | Study design | ||
| Children and adolescents | 15 | 17 | Cohort | 41 | |
| Adults | 7 | 8 | Case cross-over | 27 | |
| Elderly | 2 | 2 | Time-series | 25 | |
| Women and pregnancy | 4 | 5 | Case-control | 24 | |
| All ages | 46 | 53 | Cross-sectional | 20 | |
| Not specified | 10 | 12 | Sample size (range) | (83–11,850,884) | |
* :The classification of the continent was based on the address of the corresponding authors.† :Not clearlymentioned means no data or information were mentioned in inclusive SRs.
MAs, meta-analyses; SRs, systematic reviews.
Figure 2Regionwise and countrywise distributions of eligible SRs and MAs. The data of regions and countries are based on the information of corresponding authors. SRs, systematic reviews; MAs, meta analyses.
Figure 3Numbers of inclusive eligible SRs and MAs in six research fields between 2004 and 2018. The number of eligible SRs and MAs saw an increasing trend from 2004 to 2018. Most of the included studies were published in the last 6 years. SRs, systematic reviews; MAs, meta analyses.
The categorised list of health outcomes
| Health outcome groups | Health outcome of inclusive studies |
| Respiratory diseases | Asthma, respiratory diseases, ALRI |
| Chronic diseases | Diabetes |
| Cardiovascular diseases | Hypertension, BP, COPD, OHCA, VTE, CVD, myocardial infarction, |
| Health service records | Morbidity, hospital admissions, ED visits, mortality |
| Cancer | Lung cancer |
| Pregnancy and children | Fertility, pregnancy, birth |
| Mental disorders | Mental health, cognition, ASD |
| Other diseases | Physical inactivity, skin disease, health risks |
ALRI, acute lower respiratory infections; ASD, autism spectrum disorder; BP, blood pressure; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular diseases; ED, emergency department; OHCA, out-of-hospital cardiac arrest; VTE, venous thromboembolism.
Characteristics of included SRs and MAs based on health outcome groups
| Health outcome group | Types of air pollution* | Number of primary studies | Population group | Sample size | Key results |
| Cardiovascular diseases (24) | Fine particulate matter (10) | 32±30 | Infants and children (1) | (83, 11,850,884) | Positive (22) |
| Chronic diseases (2) | Combinations of multiple pollutants (2) | 11±-2 | All ages (2) | (402, 62,012) | Positive (2) |
| Health service records (22) | Fine particulate matter (10) | 40±38 | Infants and children (1) | (1,050, 50,756,699) | Positive (21) |
| Cancer (4) | Fine particulate matter (1) Combinations of multiple pollutants (3) | 24±10 | Adults (1) | (29, 500,000) | Positive (4) |
| Mental disorders (5) | General air pollution gas (1) Other toxic substances (1) | 16±10 | Infants and children (2) | (252, 7,203) | Positive (3) |
| Respiratory diseases (19) | Fine particulate matter (3) | 37±31 | Infants and children (11) | (186, 1,146,215) | Positive (18) |
| Pregnancy and children (6) | Fine particulate matter (2) Combinations of multiple pollutants (4) | 23±22 | Infants and children (1) | (263, 3,545,177) | Positive (6) |
| Other diseases (4) | Fine particulate matter (2) | 35±48 | Adults and old (1) | (73, 2,381,292) | Positive (3) |
Combinations of multiple pollutants are the mixture of two or more of the following air pollutants: O3, SO2, CO, NO2, PM2.5, PM10, suspended particulate matter and total suspended particles.
MAs, meta-analyses; SRs, systematic reviews.
Figure 4EGM for health outcomes affected by outdoor air pollution. The colours of the bubbles represent the confidence of included SRs and MAs; red colour represents low confidence and yellow colour represents medium confidence. The size of the bubbles indicates the relative number of included SRs and MAs, and a larger bubble represents a larger study sample size in each grid. EGM, evidence gap map; SRs, systematic reviews; MAs, meta-analyses.